Bionano Genomics (BNGO) shares fell nearly 8% in recent Thursday trading after the company lowered its Q3 revenue guidance.
The healthcare company slashed its Q3 revenue forecast to between $6.5 million and $6.8 million from a prior outlook of $7.9 million to $8.9 million.
Analysts polled by S&P Capital IQ expect $7.9 million.
Bionano added that it had $23.3 million in cash, cash equivalents, available-for-sale securities, and restricted cash as of Sept. 30, of which $11.4 million was subject to certain restrictions.
The company "has been undertaking a strategic shift in the business that is intended to allow us to become a more capital-efficient business focused on driving utilization and adoption of [optical genome mapping] from our existing installed base, with less emphasis on new placements of our [optical genome mapping] systems. This business transformation may be a factor in revenues coming in lighter than previously anticipated," Bionano Chief Executive Erik Holmlin said in a statement.
Price: 0.39, Change: -0.03, Percent Change: -7.73
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。